Key facts
- What it is: a chronic disease of excess or dysfunctional body fat that impairs health, driven by dysregulated appetite and energy balance.
- Not willpower: after weight loss the body raises hunger signals and lowers energy expenditure to defend its prior weight.
- Hormonal biology: adipose tissue and gut hormones actively regulate appetite and metabolism, which is the target of modern drugs.
- Treatment tiers: lifestyle and behaviour, medications (GLP-1 and GIP/GLP-1 receptor agonists), and metabolic surgery.
- Relapsing: stopping effective treatment typically leads to weight regain, as in a randomised semaglutide withdrawal trial.
- Linked conditions: strongly associated with type 2 diabetes and cardiovascular disease.
What obesity actually is
Obesity is a chronic disease characterised by excess or abnormal body fat that impairs health. Major medical and public-health bodies now classify it as a disease in its own right, not merely a risk factor or a lifestyle outcome — a shift that reflects decades of evidence about how the body regulates weight.
The condition sits at the centre of a web of other diseases. Excess and dysfunctional adipose tissue is closely tied to insulin resistance, type 2 diabetes, high blood pressure and cardiovascular disease, which is part of why treating obesity has effects that reach well beyond the number on a scale. Reviews of obesity pharmacotherapy frame it as a long-term medical problem that, like hypertension or diabetes, tends to require sustained management rather than a one-off intervention.
Why it is not a willpower problem
The most persistent myth about obesity is that it comes down to self-control. The biology tells a different story. Body weight is defended by a network of hormonal and neural signals — leptin from fat tissue, ghrelin from the stomach, and gut hormones released after meals — that together set hunger, fullness and how many calories the body burns at rest.
When someone loses a significant amount of weight, this system does not simply reset to the new, lower weight. Instead it responds as though the body is under threat: appetite-stimulating signals rise, satiety signals fall, and resting energy expenditure drops below what would be expected for the new body size. These adaptations can persist for months or years. The practical result is that a person who has lost weight is fighting a body actively working to regain it — which is why relapse is the norm, not the exception, and why obesity is described as a relapsing condition. None of this is a character flaw; it is physiology.
Why hormone-based drugs work
If appetite and energy balance are governed by hormones, then it follows that drugs acting on those hormone pathways can change the equation. That is exactly how the current generation of obesity medicines works. GLP-1 receptor agonists — and newer dual GIP/GLP-1 agents — mimic gut hormones that the body naturally releases after eating. They act on receptors in the gut and brain to amplify satiety, slow gastric emptying and reduce hunger, so people feel full sooner and eat less without leaning entirely on willpower.
The scientific understanding here has deepened considerably: research on the peptide hormones that regulate adipose tissue has helped explain why targeting these signalling systems produces weight loss rather than just suppressing appetite crudely. In large randomised trials, this approach clearly outperforms lifestyle change alone. Once-weekly semaglutide produced substantial, sustained weight loss in adults with overweight or obesity in the STEP 1 trial, and the dual agonist tirzepatide produced even larger reductions in the SURMOUNT-1 trial. The broader map of which molecules have this level of evidence — and which do not — is covered in our pillar guide on peptides for weight loss.
The modern treatment landscape
Because obesity is multi-factorial, effective care usually combines approaches rather than betting on one. Broadly, the landscape has three tiers:
- Lifestyle and behavioural change. Nutrition, physical activity, sleep and behavioural support remain the foundation. They improve health markers and support any other treatment, though on their own they produce modest average weight loss because of the biological defences described above.
- Medications. The GLP-1 and GIP/GLP-1 receptor agonists have reshaped obesity medicine, delivering weight loss in trials that was previously only seen with surgery. Other, older pharmacotherapies exist as well, each with its own profile. These are prescription decisions made with a clinician.
- Metabolic (bariatric) surgery. For people with more severe obesity, surgical procedures produce large and durable weight loss and can improve or resolve conditions like type 2 diabetes. They carry their own risks and require lifelong follow-up.
No single tier is "the answer" for everyone. The right combination depends on the degree of obesity, other health conditions, personal history and preference — which is why this is a clinical conversation rather than a one-size-fits-all protocol.
Why stopping treatment causes regain
One of the most important — and most misunderstood — features of obesity treatment is that it manages the condition rather than curing it. When effective treatment stops, the biology that defends a higher weight reasserts itself, and weight tends to return.
This is not speculation. In a randomised withdrawal trial (STEP 4), adults who had lost weight on semaglutide were split into two groups: those who continued the drug maintained and even extended their weight loss, while those switched to placebo regained a substantial portion of what they had lost. The pattern is consistent with how chronic-disease treatment generally works. Blood-pressure medication lowers blood pressure while it is taken; stopping it lets pressure rise again. Obesity medicines behave the same way. Framed correctly, this is not a failure of the drug — it is confirmation that obesity is a chronic condition being actively managed.
The implication for anyone using these treatments is practical: weight loss achieved on medication is maintained by ongoing management, whether pharmacological, behavioural, or both, and any decision to start, continue or stop belongs with a clinician.
A more useful way to think about it
Reframing obesity as a chronic, biologically driven disease changes what "success" looks like. It moves the goal away from a short burst of willpower toward sustained management — the same lens applied to diabetes, hypertension or high cholesterol. It also removes a layer of blame that has historically made the condition harder to treat and harder to talk about.
For people managing obesity with medication, consistency is where much of the outcome is won or lost: taking a weekly injectable on schedule, working through dose titration, and noticing side effects early. That is unglamorous, ongoing work — and it is exactly the kind of thing that is easier with a record than with memory. For the wider evidence base, our overview of peptides for weight loss and the class explainer on GLP-1 receptor agonists go deeper, and the full research library covers individual drugs and trials.
Frequently asked questions
Is obesity a disease or a lifestyle choice?
Major medical bodies classify obesity as a chronic disease, not a lifestyle choice. It reflects dysregulation of the hormonal and neural systems that control appetite, satiety and energy storage. Behaviour and environment matter, but the biology that defends a higher body weight is why willpower alone so often fails and why obesity is treated as a medical condition rather than a moral one.
Why is losing weight and keeping it off so hard?
When you lose weight, the body defends its previous weight by increasing hunger hormones, reducing satiety signals and lowering the number of calories burned at rest. These adaptations can persist long after the diet ends, which is why regain is common. It is a physiological counter-response, not a lack of discipline, and it is one reason obesity is described as a relapsing condition.
Why do hormone-based drugs work for obesity?
Drugs such as GLP-1 and GIP/GLP-1 receptor agonists act on the same gut and brain pathways that regulate appetite. By amplifying satiety signals and slowing gastric emptying, they reduce hunger and food intake, so people eat less without relying on constant willpower. Because they target the underlying biology of appetite regulation, they produce more weight loss than lifestyle change alone in clinical trials.
What are the main treatments for obesity today?
The modern landscape has three main tiers used alone or together: lifestyle and behavioural change (nutrition, activity, sleep and behavioural support); medications, most prominently the GLP-1 and GIP/GLP-1 receptor agonists; and metabolic or bariatric surgery for people with more severe obesity. Which combination is appropriate depends on the individual and is a decision made with a clinician.
Does weight come back if you stop the medication?
Usually, yes. In a randomised withdrawal trial, people who switched from semaglutide to placebo regained much of the weight they had lost, while those who continued treatment maintained or extended their loss. This mirrors how other chronic-disease treatments work: the medicine manages the condition while it is taken, and stopping removes that effect. It is why obesity is framed as a long-term condition rather than something cured by a short course.
Is obesity connected to type 2 diabetes?
Yes. Excess and dysfunctional adipose tissue contributes to insulin resistance, which is central to type 2 diabetes, and the two conditions frequently occur together. That shared biology is why several medicines developed for diabetes also produce weight loss, and why treating obesity can improve blood-sugar control. The relationship is covered in our type 2 diabetes overview.
Sources
This overview draws on peer-reviewed literature on obesity biology, pharmacotherapy and weight-loss trials:
- Obesity pharmacotherapy: current perspectives and future directions — Current Cardiology Reviews, 2013; PubMed 23092275.
- The Role of Peptide Hormones Discovered in the 21st Century in the Regulation of Adipose Tissue Functions — Genes (Basel), 2021; PubMed 34067710.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — New England Journal of Medicine, 2021; PubMed 33567185.
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — New England Journal of Medicine, 2022; PubMed 35658024.
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4) — JAMA, 2021; PubMed 33755728.
- Condition reference record: obesity.